Bortezomib Viatris is a proteasome inhibitor that helps control cell function and growth, thus destroying cancer cells.
The usual starting dose is 1.3 mg/m² of body surface area.
This medicine is given as an injection into a vein (intravenously) or under the skin (subcutaneously) by a healthcare professional. Intravenous injections are given quickly (3-5 seconds), while subcutaneous injections are given into the thigh or abdomen.
The medicine is typically given twice a week, and the total number of treatment cycles is limited, for example, up to 8 cycles (24 weeks) depending on the treatment plan.